Allevi specializes in 3D bioprinting technology, offering a range of bioprinters, bioinks, and materials designed for various applications in tissue engineering and regenerative medicine. Their patented Cell Optimized Removable Extruders (CORE™) are engineered to maintain high cell viability across diverse bioinks, enabling the printing of both hard and soft tissues without the need for additional printheads. The bioprinters feature smart auto-calibration, allowing users to easily switch needle tips and print dishes, while the versatile print bed accommodates various printing dishes, including slides and well plates. Allevi's extrusion bioprinting technology is equipped with powerful pressure regulators that facilitate the control of flow rates for a wide range of viscosities, ensuring precision in the printing process.

In addition to their bioprinting hardware, Allevi provides applications that support organ-on-a-chip models, tissue engineering, and 3D disease modeling. These applications are designed to accelerate drug discovery, cancer research, and regenerative medicine efforts by creating biomaterial-based systems that mimic the natural tissue environment. Allevi's commitment to sterility and ease of use is evident in their design, which allows for portability and straightforward sterilization. Despite the recent decision to discontinue the production of their bioprinters, Allevi remains dedicated to supporting their customers with ongoing access to materials and customer service.

United States

Allevi Develops 3D printers fof bioinks. Bioinks are materials that mimic an extracellular matrix environment to support the adhesion, proliferation, and differentiation of living cells. From GelMA to Collagen and from Hyperelastic Bone to Graphene, Allevi offers the widest range of material capabilities.

Allevi

Company Details